Depomed Inc (DEPO) 12.00 $DEPO
Nasdaq stocks posting largest percentage increases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
9.6% Return Seen to Date on SmarTrend Depomed Call (DEPO)
Comtex SmarTrend(R) - Mon May 12, 9:30AM CDT
SmarTrend identified a Downtrend for Depomed (NASDAQ
EPO) on April 7th, 2014 at $13.22. In approximately 1 month, Depomed has returned 9.65% as of today's recent price of $11.94.
DepoMed (DEPO) Is Today's Dead Cat Bounce Stock
at The Street - Mon May 12, 8:51AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference
PR Newswire - Fri May 09, 3:01PM CDT
Depomed, Inc. (NASDAQ EPO) today announced that it will be presenting at two upcoming investor conferences:
Why DepoMed Inc. Shares Were Rocked
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 12:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a specialty pharmaceutical...
Depomed Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:01PM CDT
Depomed, Inc. (Nasdaq: DEPO), today reported financial results for the first quarter ended March 31, 2014.
Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Depomed , Dendreon , and Jazz Pharmaceuticals . Depomed to report first-quarter earnings today The biopharma world will likely take a keen interest in...
Depomed May Be Setting Up In A New Base
at Investor's Business Daily - Tue May 06, 4:17PM CDT
Depomed (DEPO) may be setting up in a base, giving investors a chance to buy. But there are some caveats. One is that the base might be a late-stage pattern, since the stock has already made a big move. The base is in its eighth week, and it has...
Depomed To Report First Quarter Fiscal Year 2014 Financial Results On Thursday, May 8, 2014
PR Newswire - Wed Apr 30, 3:05PM CDT
Depomed, Inc. (NASDAQ EPO) today announced that it will release first quarter fiscal year 2014 financial results after the market closes on Thursday, May 8, 2014. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results.
Early Briefing on Pharma Equities -- Research on TherapeuticsMD, Pacira Pharma, GW Pharma, and Depomed
PR Newswire - Mon Apr 21, 10:00AM CDT
The trading session on Thursday, April 17, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,408.54, down 0.10% and the NASDAQ Composite closed at 4,095.52, up 0.23%. The S&P 500 finished the session 0.14% higher at 1,864.85. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day flat at 658.58, while it has edged lower by 0.30% in previous three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), GW Pharmaceuticals PLC (NASDAQ: GWPH) and Depomed Inc. (NASDAQ: DEPO). Free technical research on TXMD, PCRX, GWPH and DEPO can be downloaded upon signing up at:
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why DepoMed Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a biopharmaceutical company...
Depomed Announces Settlements with Two Gralise® ANDA Filers
PR Newswire - Mon Apr 14, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the other Gralise ANDA filer.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Dead Cat Bounce Stock Is DepoMed (DEPO)
at The Street - Fri Apr 04, 9:17AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 Stocks Poised for Breakouts
at The Street - Fri Mar 28, 1:42PM CDT
These stocks look ready to break out and trade higher from current levels.
Nasdaq stocks posting largest percentage increases
AP - Mon May 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
9.6% Return Seen to Date on SmarTrend Depomed Call (DEPO)
Comtex SmarTrend(R) - Mon May 12, 9:30AM CDT
SmarTrend identified a Downtrend for Depomed (NASDAQ
EPO) on April 7th, 2014 at $13.22. In approximately 1 month, Depomed has returned 9.65% as of today's recent price of $11.94. DepoMed (DEPO) Is Today's Dead Cat Bounce Stock
at The Street - Mon May 12, 8:51AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference
PR Newswire - Fri May 09, 3:01PM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that it will be presenting at two upcoming investor conferences: Why DepoMed Inc. Shares Were Rocked
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 12:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a specialty pharmaceutical...
Depomed Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:01PM CDT
Depomed, Inc. (Nasdaq: DEPO), today reported financial results for the first quarter ended March 31, 2014.
Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Depomed , Dendreon , and Jazz Pharmaceuticals . Depomed to report first-quarter earnings today The biopharma world will likely take a keen interest in...
Depomed May Be Setting Up In A New Base
at Investor's Business Daily - Tue May 06, 4:17PM CDT
Depomed (DEPO) may be setting up in a base, giving investors a chance to buy. But there are some caveats. One is that the base might be a late-stage pattern, since the stock has already made a big move. The base is in its eighth week, and it has...
Depomed To Report First Quarter Fiscal Year 2014 Financial Results On Thursday, May 8, 2014
PR Newswire - Wed Apr 30, 3:05PM CDT
Depomed, Inc. (NASDAQ
EPO) today announced that it will release first quarter fiscal year 2014 financial results after the market closes on Thursday, May 8, 2014. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Early Briefing on Pharma Equities -- Research on TherapeuticsMD, Pacira Pharma, GW Pharma, and Depomed
PR Newswire - Mon Apr 21, 10:00AM CDT
The trading session on Thursday, April 17, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,408.54, down 0.10% and the NASDAQ Composite closed at 4,095.52, up 0.23%. The S&P 500 finished the session 0.14% higher at 1,864.85. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day flat at 658.58, while it has edged lower by 0.30% in previous three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), GW Pharmaceuticals PLC (NASDAQ: GWPH) and Depomed Inc. (NASDAQ: DEPO). Free technical research on TXMD, PCRX, GWPH and DEPO can be downloaded upon signing up at:
This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 2:15PM CDT
With the SPDR S&P Biotech Index up 23% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why DepoMed Inc. Shares Temporarily Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a biopharmaceutical company...
Depomed Announces Settlements with Two Gralise® ANDA Filers
PR Newswire - Mon Apr 14, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the other Gralise ANDA filer.
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Dead Cat Bounce Stock Is DepoMed (DEPO)
at The Street - Fri Apr 04, 9:17AM CDT
Trade-Ideas LLC identified DepoMed (DEPO) as a "dead cat bounce" (down big yesterday but up big today) candidate
5 Stocks Poised for Breakouts
at The Street - Fri Mar 28, 1:42PM CDT
These stocks look ready to break out and trade higher from current levels.
